Drugs / hydroxyldaunorubicin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04842487 | Apr 2021 → Dec 2023 | diffuse large B-cell lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05093140 Background | Jun 2022 → Jun 2023 | diffuse large B-cell lymphoma, primary organ-specific lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT00725231 Background | Feb 2008 → Mar 2014 | angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | University of Göttingen | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroxyldaunorubicin | “chemotherapy cylcophosphamide, hydroxyldaunorubicin” NCT00725231 ↗ |
| Route | Intravenous | “Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1” NCT04842487 ↗ |